Diosgenone [(20S,22R,25R)-spirost-4-en-3-one, C 27 H 40 O 3 ] has been proposed as a new therapeutic alternative for the treatment of malaria. The first X-ray structure report for diosgenone was by Piro et al. [(2002) . Z. Naturforsch. Teil C, 57, [947] [948] [949] [950] in the space group P2 1 (Z 0 = 2). We now report a new polymorph in the same space group, with two molecules in the asymmetric unit. Both molecules have similar conformations, characterized by a skewed envelope A ring, which contains the C C bond conjugated with the ketone functionality at C3. The dimorphism results from a modification of the relative orientation of the molecules in the asymmetric unit: two independent molecules were arranged antiparallel in the Piro report, while they are parallel in the present determination.
Related literature
For the potential application of diosgenone as an antimalarial drug, see: Saez et al. (1998) ; Echeverri et al. (2001) . For a biotransformation of diosgenone, see: Wang et al. (2007 Wang et al. ( , 2009 . For the synthesis of diosgenone, see: Hunter & Priest (2006) . For the structure of a monoclinic polymorph of diosgenone, see: Piro et al. (2002) .
Experimental
Crystal data growing, since it has been proposed by a group working in Colombia as a new therapeutic alternative for the treatment of malaria (Echeverri et al., 2001; Saez et al., 1998) . This claim is in line with the fact that Solanun nudum is used by the community of Tumaco (Narino, Colombia) as a cure for malaria. A more academic interest is related to the biotransformation of diosgenone to isonuatigenone (C25-hydroxylation), which rearranges in acid media into nuatigenone, a rare nuatigenin-type steroid (Wang et al., 2007 (Wang et al., , 2009 . These studies allow a postulate for a new pathway of diosgenin metabolism.
The X-ray structure for diosgenone was described in space group P2 1 (Piro et al., 2002; CSD refcode: LUKXAQ) . We have now discovered that a second polymorph in the same space group may be obtained if the crystallization is carried out by slow evaporation of an AcOEt/acetone (4:1) solution, while Piro et al. crystallized diosgenone from an ethanolic solution. The asymmetric unit, as in the previous report, contains two independent molecules (Fig. 1) , with very similar conformations. The r.m.s. deviation for the fitted molecules is less than 0.2 Å. No significant conformational modification is observed by comparing molecules in both polymorphs: calculated r.m.s. deviations for pairs of molecules taken in different crystal forms are in the range 0.17 to 0.32 Å, the largest deviations being for the methyl group bonded to C25 in the F ring. However, simulated X-ray powder patterns for each form (Fig. 2) show clearly that these crystal forms are dimorphic. The crystal modification should thus be due to a reorientation of independent molecules in the asymmetric unit. In the case of the previously described structure (Piro et al., 2002) , the asymmetric unit may be described with two molecules arranged in such a way that the A→F rings sequence of one molecule is oriented antiparallel to the A→F sequence of the other one. In contrast, the asymmetric unit of the title polymorph described herein includes two parallel molecules (see insets in Fig. 2 ).
The title steroid was synthesized from diosgenin using a Jones oxidation described previously (Hunter & Priest, 2006) . Diosgenine (2 g, 4.8 mmol) was dissolved in a CH 2 Cl 2 /acetone mixture (40 and 132 ml) and this solution was cooled to 263 K. Under stirring, the Jones reagent was added slowly, over 10 min., maintaining the temperature below 283 K. After addition, the mixture was further stirred at room temperature, until the color turned from orange to green. 2-Propanol was then added in order to eliminate the unreacted Jones reagent, and the product was extracted with AcOEt, washed with water, and dried over Na 2 SO 4 . The crude product was purified by chromatography on silica gel (AcOEt/hexane, 1:9 v/v), affording the title steroid (yield: 20%) and the Δ 4 -3,6 dione derivative. 
Refinement
All H atoms were placed in idealized positions and refined as riding on their carrier atoms. Isotropic displacement parameters were calculated as U iso (H) = xU eq (carrier atom) where x = 1.5 for methyl H atoms and x = 1.2 otherwise.
Absolute configuration was assigned from chiral centers with known configuration in the steroidal nucleus, and measured Friedel pairs (3382) were merged. 
Computing details

Figure 1
The asymmetric unit of the title compound. Displacement ellipsoids for non-H atoms are drawn at the 50% probability level.
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Figure 2
Simulated powder diffraction patterns for both P2 1 polymorphs of the title compound. Spectra were calculated with Mercury (Macrae et al., 2008) with λ = 1.5418 Å, by steps of 0.002° and peak shape defined by a FWHM of 0.05° in 2θ.
The insets for each polymorph represent the asymmetric unit for the crystal, omitting H atoms for clarity. The asymmetric unit for the previously reported form (Piro et al., 2002) has been regrouped in order to be comparable to the unit used for the refinement of the new polymorph.
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